NOVAVAX INC. news, videos and press releases
For more news please use our advanced search feature.
NOVAVAX INC. - More news...
NOVAVAX INC. - More news...
- Novavax Announces Changes to Board of Directors
- Novavax to Participate in Upcoming March Investor Conferences
- Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
- Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
- Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
- Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
- Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
- Novavax to Participate in Jefferies London Healthcare Conference
- Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
- U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
- Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
- NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
- Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
- Novavax to Participate in Upcoming September Conferences
- Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
- Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
- Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
- Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
- Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
- Novavax to Participate in 2024 Jefferies Global Healthcare Conference
- Novavax to Participate in BofA Securities 2024 Health Care Conference
- Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
